A Novel Effective Treatment of Advanced Prostate Cancer: A Single Case Report

Abstract

A novel treatment for prostate cancer, based on the Tvec /pembroluzimab technology -supported by activation of innate immunity is reported. The effect has been striking. Reduction of PSA from 60 𝜇g/Liter to undetectable in 6 weeks, reduction of serum LDH from almost 1000 U/L to under 200 (normal) in 8 weeks, extensive necrosis in the tumor tissue as revealed by MR. The treatment gave no serious side-effects.